Hamburg, Germany - 18 December 2014: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) disclosed today that it achieved multiple milestones in ongoing alliances with its strategic research partners. The milestones were reached in its multi-target collaboration with Bayer HealthCare ("Bayer") in endometriosis and within its partnership with Janssen Pharmaceuticals, Inc. ("Janssen") for the EVT100 series for the treatment of CNS diseases. These milestones trigger revenues of approx. EUR 8 m in total which will be recognised in the financial year 2014.
Multi-target collaboration with Bayer
In its multi-target collaboration with Bayer, Evotec has reached important milestones for the transition of certain molecules into pre-clinical development for the treatment of endometriosis. These milestones were achieved under the agreement between Evotec and Bayer signed in October 2012. The goal of this collaboration is to identify three clinical candidates within the five-year alliance. Both parties contribute innovative drug targets and high-quality technology infrastructures and share the responsibility for early research and pre-clinical characterisation of potential clinical candidates in the disease area of endometriosis.
Cooperation with Janssen
In its collaboration with Janssen on a NR2B subtype selective NMDA-antagonist portfolio for development against CNS diseases, Evotec has reached an important validation milestone for a new compound.